Jan. 20, 2020: Protease inhibitors and heart attack risk; HIV status and pericardial adipose tissue volume; cardiovascular risk profiles on TDF vs. TAF; hemostatic profiles in older people living with HIV.
Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.
Oct. 3, 2019: The sexual divide in HIV-related heart disease; weight gain among women on integrase inhibitors; HIV's association with non-specific health conditions; hopeful trends in self-reported neurocognitive impairment.
Even in the modern treatment era, HIV-positive men who have sex with men are developing diabetes at an extremely high rate.
Long-term glucose disorders; anal vs. cervical HPV; PrEP adherence among U.S. veterans; economic incentives to spur HIV testing.
Researchers found that people who were cured of hepatitis C virus underwent "significant improvement" in blood sugar levels and in many cases participants' doctors were able to reduce the dose of medicines used to help control blood sugar.
Researchers working with a U.S. veterans group conducted a study to see how weight gain affects diabetes risk in veterans with and without HIV infection.
Diabetes mellitus occurs at an increased frequency in people with HIV infection and may develop at earlier stages than it does in the general population.
Diabetes prevalence stood at 10.3% among HIV-positive adults in a nationally representative U.S. sample, which was 3.8% higher than in the general population.